Kaja Zuwala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/758602/publications.pdf

Version: 2024-02-01

623574 839398 18 428 14 18 citations g-index h-index papers 18 18 18 725 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. Aids, 2019, 33, 1315-1325.	1.0	66
2	Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses. Advanced Healthcare Materials, 2017, 6, 1700748.	3.9	45
3	Albumin–Polymer–Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles. ACS Macro Letters, 2016, 5, 1089-1094.	2.3	34
4	Macromolecular (pro)drugs in antiviral research. Polymer Chemistry, 2014, 5, 6407-6425.	1.9	30
5	Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs. Chemical Communications, 2014, 50, 14498-14500.	2.2	30
6	Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV. Chemical Science, 2015, 6, 264-269.	3.7	25
7	Highly Active Macromolecular Prodrugs Inhibit Expression of the Hepatitis C Virus Genome in the Host Cells. Advanced Healthcare Materials, 2015, 4, 65-68.	3.9	25
8	The Nucleocapsid Protein of Human Coronavirus NL63. PLoS ONE, 2015, 10, e0117833.	1.1	23
9	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. EBioMedicine, 2019, 45, 328-340.	2.7	22
10	Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1. Molecular Pharmaceutics, 2016, 13, 2397-2410.	2.3	20
11	Polymers Fight HIV: Potent (Pro)Drugs Identified Through Parallel Automated Synthesis. Advanced Healthcare Materials, 2015, 4, 46-50.	3.9	19
12	Characterization of HIV-1 Infection and Innate Sensing in Different Types of Primary Human Monocyte-Derived Macrophages. Mediators of Inflammation, 2013, 2013, 1-11.	1.4	16
13	HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat. Chemical Science, 2016, 7, 2353-2358.	3.7	16
14	Long-Acting, Potent Delivery of Combination Antiretroviral Therapy. ACS Macro Letters, 2018, 7, 587-591.	2.3	15
15	Macromolecular Prodrugs of Ribavirin: Structure–Function Correlation as Inhibitors of Influenza Infectivity. Molecular Pharmaceutics, 2017, 14, 234-241.	2.3	14
16	Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects. Journal of Controlled Release, 2018, 275, 53-66.	4.8	13
17	Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity. Advanced Healthcare Materials, 2016, 5, 534-540.	3.9	11
18	Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. ACS Macro Letters, 2017, 6, 935-940.	2.3	4